VR Adviser LLC Sells 1,001,297 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

VR Adviser LLC trimmed its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 29.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,457,348 shares of the biotechnology company's stock after selling 1,001,297 shares during the quarter. Astria Therapeutics makes up approximately 1.5% of VR Adviser LLC's holdings, making the stock its 18th biggest position. VR Adviser LLC owned 4.35% of Astria Therapeutics worth $21,969,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vestal Point Capital LP boosted its stake in Astria Therapeutics by 4.5% in the 4th quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company's stock worth $37,369,000 after purchasing an additional 180,000 shares during the period. Fcpm Iii Services B.V. bought a new position in shares of Astria Therapeutics during the 4th quarter valued at approximately $25,680,000. Vanguard Group Inc. boosted its position in shares of Astria Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company's stock valued at $23,936,000 after acquiring an additional 41,833 shares during the last quarter. Northern Trust Corp boosted its position in shares of Astria Therapeutics by 4.5% during the 4th quarter. Northern Trust Corp now owns 458,234 shares of the biotechnology company's stock valued at $4,097,000 after acquiring an additional 19,893 shares during the last quarter. Finally, Redmile Group LLC boosted its position in shares of Astria Therapeutics by 11.4% during the 4th quarter. Redmile Group LLC now owns 346,278 shares of the biotechnology company's stock valued at $3,096,000 after acquiring an additional 35,394 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ATXS shares. Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Wedbush restated an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 11th. Cantor Fitzgerald restated an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. Finally, JMP Securities started coverage on Astria Therapeutics in a report on Friday, January 31st. They set an "outperform" rating and a $26.00 price target on the stock. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $30.00.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS traded up $0.16 on Thursday, hitting $4.08. 943,267 shares of the company's stock were exchanged, compared to its average volume of 372,382. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92. The stock has a market capitalization of $230.25 million, a price-to-earnings ratio of -1.95 and a beta of 0.45. The business's 50 day simple moving average is $4.80 and its two-hundred day simple moving average is $7.19.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Equities analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.